David Mcgibney
Member
AdAlta
Australia
Biography
David is an experienced clinical and pharmaceutical development professional and runs his own lifescience consultancy practice. He previously held senior R&D positions at Pfizer, including SVP and Head of European R&D 1998-2001 and VP and Head of European Clinical Research and Regulatory Affairs 1992-1998. During his tenure at Pfizer, David was instrumental in the successful development and registration of numerous medicines, including Amlodipine (Norvasc™), Doxazosin (Cardura™), Fluconazole (Diflucan™), Sertraline (Zoloft™), Sildenafil (Viagra™), Dofetilde (Tikosyn™), Eletriptan (Relpax™), Voriconazole (VFend™), Trovafloxacin (Trovan™), Ziprasidone (Geodon™), Darifenacin (Enablex™), Azithromycin (Zithromax™), and Donepezil (Aricept™). From 2002-2004, David was Executive Director and Head of Drug Discovery and Development at Avidex Ltd. As a consultant to the pharmaceutical industry, he works closely with biotechnology companies, lifescience investors, and non-profit healthcare organizations, including Medicines for Malaria Venture (Chairman of Expert Scientific Advisory Committee and Member of Global Safety Board and Access and Product Management Advisory Committee), NightstaRx (Chairman of Development Advisory Board), Convergence Ltd (Board observer), Vantia Ltd (Chairman of Development Subcommittee) and Kalvista Ltd (Chairman of Advisory Committee). He is a clinical and product development advisor to Heptares Therapeutics as well as to venture investors Imperial Innovations, Apposite Capital, Abingworth, MVM Life Science Partners, Syncona Partners and Radius Ventures.
Research Interest
Pharmaceutics & Biopharmaceutics Drug Targeting & Drug Development Pharmaceutical Research Pharmaceutical Materials Pharmaceutical Formulations Pharmaceutical Biotechnology Pharmaceutical Nanotechnology Pharmaceutical Technology Pharmaceutical Manufacturing Pharmaceutical Engineering Drug Delivery Technologies Medical Devices Drug Regulatory Affairs Pharmaceutical Management
